genetic screening

The Golden Age of Healthcare Investing is Now

By Ted Driscoll / March 11, 2013 / 0 Comments

The human genome evolved for us as Paleolithic cavemen, arming us to cope with leopards, communicable diseases, infections, parasites and starvation. But modern society has succeeded in taming most of those risks, and now, ironically, our biggest health challenges are largely a byproduct of our success. As we extend our lifespan, cancer and cardiac disease increase in incidence. We confront an epidemic of diabetes and obesity related diseases largely caused by overconsumption and inactivity. Our genome never evolved to benefit obese 70 year olds. Cavemen didn’t typically live past 40 and didn’t drink high-fructose corn syrup in Big Gulps.

Read More

Congratulations: Quest Diagnostics to offer access to Natera’s Panorama, non-invasive prenatal test

By Ted Driscoll / February 23, 2013 / 0 Comments

Congratulations to Natera—our portfolio company who is the leading innovator in prenatal genetic testing! Yesterday they announced a major deal with Quest Diagnostics (NYSE: DGX), the world’s leading diagnostic information services company. Quest Diagnostics will offer physicians access to Panorama™, the new non-invasive prenatal test developed by Natera. (Read the Quest Press Release) Panorama uses […]

Read More

Ted Driscoll featured in Pharmalot, Op-Ed: Entering The Golden Age Of Big Data

By Claremont Creek Alerts / February 23, 2013 / 0 Comments

February 20, 2013   source: the original post by Ed Silverman appeared in Pharmalot As drug development and diagnostics increasingly converge, the advent of personalized medicine is increasing all the time. Of course, we are not quite there yet, but the advent of electronic medical records and the genome are inching us closer all the time. But […]

Read More

AssureRx: advanced genomics tools inform patient response to psychotropic therapy

By Brad Webb / September 17, 2012 / 0 Comments

Bloomberg reporter Ryan Flinn recently wrote an article on Brain Scans Seek Best Drug Match for Depression Patients. The article summarizes some of the technologies that are being used by clinicians to assist in diagnosis and treatment of depression, and focused on technologies provided by two companies. The first company profiled uses a technology that matches […]

Read More
AssureRX

Claremont Creek Ventures portfolio company AssureRx Health wins award for innovation

By John Steuart / March 8, 2012 / 0 Comments

March 7, 2012  source: Angel Capital Association (ACA) AssureRx Health, Inc. Receives 2012 ACA Luis Villalobos Award for Innovation  Angel Capital Association Recognizes Company For Industry-leading Personalized Medicine Solution Hats off to one of my portfolio companies, AssureRx today received the the 2012 Luis Villalobos Award from the Angel Capital Association (ACA), the trade association of […]

Read More

Claremont Creek Ventures’ portfolio company AssureRX updates its psychiatric drugs screening test

By Claremont Creek Alerts / January 18, 2012 / 0 Comments

January 18, 2012  source: MedCity News   Personalized medicine company AssureRx Health has released the next-generation version of its genetic screening test for psychiatric drugs. The Cincinnati-area company’s GeneSightRx test, which helps doctors pick the right psychiatric drugs for patients based on their genes, was launched in 2009. The test uses a cheek swab, mathematical […]

Read More

Meet our team

Claremont Creek Ventures was founded in 2005 by Nat Goldhaber, John Steuart and Randy Hawks to pursue early stage investing in exceptional technology startups.

Nat_Boldhaber7718 -1200px

NAT GOLDHABER

Nat Goldhaber is a co-founder of Claremont Creek Ventures. 

Brad_Webb8124 1200px crop

BRAD WEBB

Brad is focused on the role of genomics and biomarker data analytics in driving the next generation of diagnostics and drug development.

Randy_Hawks7690 -1200px

RANDY HAWKS

Randy Hawks is a co-founder of Claremont Creek Ventures.

Post Categories

Archives